Search
Yifan Pharmaceutical Anticipates Further Sales Surge for Core Product Yilishi in 2025
2025-06-03 /
Read about 0 minute
Author：小编
Yifan Pharmaceutical's flagship product, Yilishi, notched remarkable achievements in 2024, surpassing 270,000 units in domestic sales and generating over 500 million yuan in net terminal revenue. Looking ahead, the company forecasts an even greater uptick in sales for 2025, with a notable contribution from overseas markets. Despite delays caused by packaging and supply chain challenges, the introduction of Yilishi in the US market is now scheduled to commence in mid-June 2025, promising to further bolster sales figures.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
